Related Experiment Video
Updated: May 21, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy
Laura C McAdam1, Amanda L Mayo, Benjamin A Alman
1Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. lmcadam@hollandbloorview.ca
Abstract:
Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long-term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cardiomyopathy II: Dilated Cardiomyopathy
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Satellite Stem Cells and Muscular Dystrophy
Cardiomyopathy V: Interprofessional Care

